AIMS: To assess the cost-effectiveness of implantable loop recorders (ILRs) in people with transient loss of consciousness (TLoC), which, after initial assessment and specialist cardiovascular assessment, is either suspected to be arrhythmic in origin or remains unexplained. This analysis was conducted to inform clinical guideline recommendations made by the National Institute for Health and Clinical Excellence (NICE) on the management of TLoC. METHODS AND RESULTS: Decision analytic modelling was used to estimate the costs and benefits of using ILRs compared with a strategy of no further diagnostic testing. Diagnostic outcomes were estimated from a systematic review and used to populate a decision tree model. To capture the main consequences of diagnosis, the costs and benefits of treatment for several clinically significant arrhythmias were estimated within the model. We used a cost-utility approach, in which benefits are measured using quality adjusted life years (QALYs), and took a UK National Health Service (NHS) and personal social services perspective. The cost per QALY was £17,400 in patients with unexplained syncope and £16,400 in patients with suspected arrhythmic syncope. Sensitivity analysis found that the cost-effectiveness estimates are fairly robust despite the areas of uncertainty identified in the evidence and assumptions used to inform the model. CONCLUSIONS: Implantable loop recorder monitoring is likely to be a cost-effective strategy in people presenting to the UK NHS who are experiencing infrequent episodes of TLoC which either remain unexplained or are suspected to be arrhythmic after initial assessment and specialist cardiovascular assessment. Implantable loop recorder monitoring has been recommended by NICE for these populations.
AIMS: To assess the cost-effectiveness of implantable loop recorders (ILRs) in people with transient loss of consciousness (TLoC), which, after initial assessment and specialist cardiovascular assessment, is either suspected to be arrhythmic in origin or remains unexplained. This analysis was conducted to inform clinical guideline recommendations made by the National Institute for Health and Clinical Excellence (NICE) on the management of TLoC. METHODS AND RESULTS: Decision analytic modelling was used to estimate the costs and benefits of using ILRs compared with a strategy of no further diagnostic testing. Diagnostic outcomes were estimated from a systematic review and used to populate a decision tree model. To capture the main consequences of diagnosis, the costs and benefits of treatment for several clinically significant arrhythmias were estimated within the model. We used a cost-utility approach, in which benefits are measured using quality adjusted life years (QALYs), and took a UK National Health Service (NHS) and personal social services perspective. The cost per QALY was £17,400 in patients with unexplained syncope and £16,400 in patients with suspected arrhythmic syncope. Sensitivity analysis found that the cost-effectiveness estimates are fairly robust despite the areas of uncertainty identified in the evidence and assumptions used to inform the model. CONCLUSIONS: Implantable loop recorder monitoring is likely to be a cost-effective strategy in people presenting to the UK NHS who are experiencing infrequent episodes of TLoC which either remain unexplained or are suspected to be arrhythmic after initial assessment and specialist cardiovascular assessment. Implantable loop recorder monitoring has been recommended by NICE for these populations.
Authors: Dariusz Dudek; Waldemar Banasiak; Wojciech Braksator; Jacek Dubiel; Tomasz Grodzicki; Piotr Hoffman; Mariusz Kuśmierczyk; Grzegorz Opolski; Piotr Ponikowski; Jacek Różański; Jerzy Sadowski; Wojciech Wojakowski; Marcin Grabowski; Katarzyna Bondaryk; Jacek Walczak; Izabela Pieniążek; Maciej Grys; Anna Lesiak-Bednarek; Piotr Przygodzki Journal: Cardiol J Date: 2019-02-14 Impact factor: 2.737
Authors: Martin Huemer; Ann-Kristin Becker; Alexander Wutzler; Philipp Attanasio; Abdul S Parwani; Philipp Lacour; Leif-Hendrik Boldt; Burkert Pieske; Wilhelm Haverkamp; Florian Blaschke Journal: Cardiol J Date: 2018-02-05 Impact factor: 2.737
Authors: Claudia I Rinciog; Laura M Sawyer; Alexander Diamantopoulos; Mitchell S V Elkind; Matthew Reynolds; Stylianos I Tsintzos; Paul D Ziegler; Maria E Quiroz; Claudia Wolff; Klaus K Witte Journal: Open Heart Date: 2019-06-20
Authors: Brad S Sutton; Sarah L Bermingham; Alexander Diamantopoulos; Sarah C Rosemas; Stelios I Tsintzos; Ying Xia; Matthew R Reynolds Journal: Open Heart Date: 2021-02